# AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors

> **NCT06911333** · PHASE1,PHASE2 · RECRUITING · sponsor: **Avelos Therapeutics Inc.** · enrollment: 36 (estimated)

## Conditions studied

- Solid Tumor, Adult
- Tumor, Solid
- Solid Tumor
- Solid Tumor, Unspecified, Adult
- Solid Tumor Cancer
- Solid Tumors Refractory to Standard Therapy
- Solid Tumor in Advanced Stage

## Interventions

- **DRUG:** AD1208

## Key facts

- **NCT ID:** NCT06911333
- **Lead sponsor:** Avelos Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-11
- **Primary completion:** 2029-06-30
- **Final completion:** 2030-02-20
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2025-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06911333

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06911333, "AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06911333. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*